First Author: E.Önder TURKEY
Co Author(s): L. Karabas B. Ozkan S. Kaya E. Kesim N. Yuksel
Back to previous
To investigate the effect of intravitreal dexamethasone injection in patients with intravitreal ranibizumab-resistant diabetic macular edema (DME)
32 eyes of 26 patients with diabetic retinopathy were assessed in University of Kocaeli, Faculty of Medicine, Department of Ophthalmology.
32 eyes of 26 patients with diabetic retinopathy were assessed. Patients who were thought to be intravitreal ranibizumab resistant diabetic macular edema after the third times of injections were included in the study and intravitreal dexamethasone was administered to them. The macular thickness and visual acuity of the patients were determined in the first and second months after the third ranibizumab injections and the first dexamethasone injection. The data of both agents were compared and the results were evaluated by statistical analysis.
The central macular thickness was compared before ranibizumab injection and at the first month after the third ranibizumab injection and a significant decrease was observed. The central macular thickness was compared before dexamethasone injection and at the first month after injection, and a significant decrease was observed. The difference between central macular thicknesses after the third injection of ranibizumab was 115 microns and after the first injection of dexamethasone was 254 microns. The rate of the reduction of central macular thickness of dexamethasone injection was found to be higher than ranibizumab injeciton and this was statistically significant (p =0.03). There was no significant difference in visual acuity before and after the third intravitreal ranibizumab injection(p: 0.687) and a significant difference in visual acuity after the first intravitreal dexamethasone injection compared to before injection (p: 0.03).
When the results are evaluated, intravitreal dexamethasone injection in ranibizumab-resistant diabetic macular edema patient group is thought to be more effective in decreasing central macular thickness. However, more extensive studies are needed with large patient series.